Clinical Trial

Evaluation of the Efficacy and Safety of Microneedling Combined With Botulinum Toxin-A Versus Meso-Botox Injection in the Treatment of Atrophic Acne Scars: A Split-face Comparative Study

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2024 (before its estimated April 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Post-acne scars are psychologically disappointing and therapeutically challenging condition. No standard treatment for atrophic acne scars. Micro-Botox, is a highly diluted BTX-A which could be injected safely intra-dermally. It targets the superficial fibers of facial muscles, sweat, and sebaceous glands inducing pores shrinkage, decreasing the sebum and excessive sweating, in addition to face lifting and reducing fine wrinkles without affecting emotions, this subsequently makes the skin tighter and gives the facial skin a smooth appearance. Also, BTX-A appears to have an inhibitory effect on fibroblasts and collagen remodeling activity, in addition to releasing muscular tension at scar edges through superficial muscle relaxation. So, it can reduce the tethering and pulling effect of the muscles surrounding the acne scars. Also, it has anti-inflammatory and angiogenesis induction effects. Therefore, micro-Botox is believed to improve acne scars. Therefore, it will be interesting to compare the efficacy and safety of microneedling combined with BTX-A versus meso-Botox injection in the treatment of atrophic acne scars through a split-face clinical study.
Trial Details
NCT Number NCT06544993
Lead Sponsor Sohag University
Conditions Atrophic Acne Scar
Enrollment 30 participants
Start Date 2024-05-01
Primary Completion 2025-04-01 (estimated)
Study Completion 2025-05-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-09